English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Objective: The unresectable stage III non-small-cell lung cancer (NSCLC) is usually treated with concurrent chemo-radiotherapy. To overcome the normal tissue toxicity without affecting tumor control a new regimen was modified as CHARTWEL (continuous accelerated hyper-fractionated radiotherapy week-end less). In the present study we compared the results (in terms of loco-regional control & overall survival) of induction CT followed by CHARTWEL v/s conventional radiotherapy+chemotherapy. Materials and Methods: Total 50 patients with unresectable stage III NSCLC were first given four cycles of neo-adjuvant chemotherapy (Inj. Cisplatin 75 mg/m 2 divided into day 1 and day 2 and Inj. Paclitaxel 175 mg/m 2 intravenous on day 1). After it 25 patients received 58.5Gy/39fr in 17 days (1.5 Gy/# , 3#/day, 6 hours apart) week-end less while other 25 received 66Gy/33fr with conventional fractionation. Disease response was evaluated by RECIST criteria at 6 month. Then follow up was done after 1, 2 and 3 year to evaluate the overall survival. Results: Overall 28% of patients in study arm and 20% in control arm had complete response at 6 month. Loco-regional disease control was 44% and 32% in study & control arm respectively (p value>0.05) at 6 month. There was no statistical difference in grades of toxicities. Overall survival rates (primary end point) at 1, 2 and 3 years were 60%, 16.67% and 16.67% respectively in control (conventional RT) arm while in study (CHARTWEL) arm those values were 60%,30% & 20% respectively, but statistically nonsignificant. Conclusion: Study suggests that CHARTWEL can be used in combination with neo-adjuvant chemotherapy to treat locally advanced lung cancer. Although, large multi-variate studies still needed to ascertain the need and benefits of CHARTWEL with neo-adjuvant chemotherapy.

Comparison of CHARTWEL and conventional radiotherapy after neoadjuvant chemotherapy in locally advanced non small cell lung cancer